Abstract
Prostate cancer (PCa) is a worldwide issue, with a rapid increase in its occurrence and mortality. Over the years, various strategies have been implemented to overcome the hurdles that exist in the treatment of PCa. Consistently, there is a change in opinion about the methodologies in clinical trial that have engrossed towards the treatment of PCa. Currently, there is a need to resolve these newly recognized challenges by developing newer rational targeting systems. The ongoing clinical protocol for the therapy using different targeting systems is undertaken followed by local targeting to cancer site. A number of new drug targeting systems like liposomes, nanoemulsions, magnetic nanoparticles (MNPs), solid lipid nanoparticles, drug-peptide conjugate systems, drug-antibody conjugate systems, epigenetic and gene therapy approaches, and therapeutic aptamers are being developed to suit this protocol. Recent advancements in the treatment of PCa with various nanocarriers have been reported with respect to newly identified biological barriers and intended to solve the contexts. This review encompasses the input of nanotechnology in particular targeting of PCa which might escape the lifethreatening side effects and potentially contribute to bring fruitful clinical outcomes.
Keywords: Prostate cancer (PCa), nanocarrier systems, magnetic nanoparticles (MNPs), nanoemulsion systems, drug-peptide conjugate systems, drug-antibody conjugate systems, therapeutic apatamers.
Graphical Abstract
[http://dx.doi.org/10.21037/tau.2017.12.24] [PMID: 29594023]
(b) Guo, X.; Zhang, C.; Guo, Q.; Xu, Y.; Feng, G.; Li, L.; Han, X.; Lu, F.; Ma, Y.; Wang, X.; Wang, G. The homogeneous and heterogeneous risk factors for the morbidity and prognosis of bone metastasis in patients with prostate cancer. Cancer Manag. Res., 2018, 10, 1639-1646.
[http://dx.doi.org/10.2147/CMAR.S168579] [PMID: 29970963]
[http://dx.doi.org/10.1016/J.crad.2018.12.003] [PMID: 30611559]
[http://dx.doi.org/10.18295/squmj.2017.17.04.008] [PMID: 29372084]
[http://dx.doi.org/10.2174/1568026619666190125145836] [PMID: 30686255]
[http://dx.doi.org/10.3389/fphar.2017.00153] [PMID: 28400729]
[http://dx.doi.org/10.1007/s11095-013-1214-1] [PMID: 24135934]
[http://dx.doi.org/10.1016/j.ctrv.2013.10.005] [PMID: 24216226]
[http://dx.doi.org/10.1038/nrc.2016.108] [PMID: 27834398]
[http://dx.doi.org/10.1021/acs.biomac.5b00913] [PMID: 26335533]
[http://dx.doi.org/10.2217/nnm-2018-0034]
[http://dx.doi.org/10.1016/B978-0-12-814513-5.00016-7]
[http://dx.doi.org/10.3390/ijms18051017] [PMID: 28486411]
[http://dx.doi.org/10.2147/IJN.S139080] [PMID: 30310278]
[http://dx.doi.org/10.1002/adhm.201700646] [PMID: 28795530]
[http://dx.doi.org/10.1016/j.canlet.2019.01.045] [PMID: 30763718]
[PMID: 25620167]
[PMID: 23293520]
[http://dx.doi.org/10.4172/2157-7439.1000103e]
(b) Tannock, I.F.; Lee, C.M.; Tunggal, J.K.; Cowan, D.S.; Egorin, M.J. Limited penetration of anticancer drugs through tumor tissue: A potential cause of resistance of solid tumors to chemotherapy. Clin. Cancer Res., 2002, 8(3), 878-884.
[PMID: 11895922]
[http://dx.doi.org/10.3390/cancers3032888] [PMID: 24212938]
[http://dx.doi.org/10.1038/nrd2614] [PMID: 18758474]
(b) Zahreddine, H.; Borden, K.L. Mechanisms and insights into drug resistance in cancer. Front. Pharmacol., 2013, 4, 28.
[http://dx.doi.org/10.3389/fphar.2013.00028] [PMID: 23504227]
[http://dx.doi.org/10.1016/j.jconrel.2017.06.001] [PMID: 28583444]
[http://dx.doi.org/10.2217/epi.14.34] [PMID: 25333850]
[http://dx.doi.org/10.1038/nature05918] [PMID: 17522676]
[http://dx.doi.org/10.1002/cbic.201000195] [PMID: 21243710]
[http://dx.doi.org/10.3892/or.2012.2192] [PMID: 23254386]
[http://dx.doi.org/10.1007/3-540-31181-5_12]
[http://dx.doi.org/10.1038/nsmb1337] [PMID: 17984963]
[http://dx.doi.org/10.2217/epi.12.74] [PMID: 23414320]
[http://dx.doi.org/10.1038/nrg1379] [PMID: 15211354]
(b) Wang, N.; Li, Q.; Feng, N-H.; Cheng, G.; Guan, Z-L.; Wang, Y.; Qin, C.; Yin, C-J.; Hua, L-X. miR-205 is frequently downregulated in prostate cancer and acts as a tumor suppressor by inhibiting tumor growth. Asian J. Androl., 2013, 15(6), 735-741.
[http://dx.doi.org/10.1038/aja.2013.80] [PMID: 23974361]
[http://dx.doi.org/10.1007/s12272-014-0459-5] [PMID: 25134927]
[http://dx.doi.org/10.1002/j.1552-4604.1989.tb03381.x] [PMID: 2754024]
[http://dx.doi.org/10.4103/0975-1483.76413] [PMID: 21607048]
[http://dx.doi.org/10.1021/bc400521r] [PMID: 24533729]
[http://dx.doi.org/10.1038/srep26895] [PMID: 27241877]
[http://dx.doi.org/10.7314/APJCP.2013.14.7.4347] [PMID: 23992001]
[http://dx.doi.org/10.1039/C5RA23067E]
[http://dx.doi.org/10.1007/s13346-017-0424-1] [PMID: 28849577]
[http://dx.doi.org/10.1007/s11596-017-1742-8] [PMID: 28585133]
[PMID: 28694767]
[PMID: 27226712]
[http://dx.doi.org/10.1016/j.nano.2016.08.017] [PMID: 27565690]
[http://dx.doi.org/10.1016/j.canlet.2018.04.017] [PMID: 29678549]
[http://dx.doi.org/10.1016/j.jsps.2018.03.009] [PMID: 30202231]
[http://dx.doi.org/10.1080/10717544.2017.1422300] [PMID: 29313393]
[http://dx.doi.org/10.1155/2018/4719790]
[http://dx.doi.org/10.1002/jcb.26727] [PMID: 29380900]
[http://dx.doi.org/10.1166/jnn.2018.15292] [PMID: 29442621]
[http://dx.doi.org/10.1007/s11664-018-6309-3]
[http://dx.doi.org/10.1111/cas.12839] [PMID: 26495901]
[http://dx.doi.org/10.1021/nn500152u] [PMID: 24730557]
[http://dx.doi.org/10.1002/anie.201500286] [PMID: 25802144]
[http://dx.doi.org/10.1021/bm401777w] [PMID: 24392665]
[http://dx.doi.org/10.1016/j.jconrel.2015.08.032] [PMID: 26307351]
[http://dx.doi.org/10.1016/j.actbio.2015.05.021] [PMID: 26013038]
[http://dx.doi.org/10.1016/j.biomaterials.2013.10.063] [PMID: 24211077]
[http://dx.doi.org/10.1016/j.bbrc.2015.09.036] [PMID: 26362176]
[http://dx.doi.org/10.1016/j.colsurfb.2016.03.071] [PMID: 27058278]
[http://dx.doi.org/10.3390/ijms16059573] [PMID: 25927579]
[http://dx.doi.org/10.1002/jbm.a.35300] [PMID: 25088162]
[http://dx.doi.org/10.1016/j.ejmech.2015.05.028] [PMID: 26021708]
[http://dx.doi.org/10.1016/j.ijpharm.2014.03.016] [PMID: 24607216]
(b) Chowdhury, P.; Roberts, A.M.; Khan, S.; Hafeez, B.B.; Chauhan, S.C.; Jaggi, M.; Yallapu, M.M. Magnetic nanoformulations for prostate cancer. Drug Discov. Today, 2017, 22(8), 1233-1241.
[http://dx.doi.org/10.1016/j.drudis.2017.04.018] [PMID: 28526660]
[http://dx.doi.org/10.1021/acsami.6b10029] [PMID: 27786455]
[http://dx.doi.org/10.1016/j.ijpharm.2015.07.042] [PMID: 26200751]
[http://dx.doi.org/10.1038/mtna.2016.43] [PMID: 28131285]
[http://dx.doi.org/10.1208/s12249-017-0772-7] [PMID: 28397161]
[http://dx.doi.org/10.2147/IJN.S152485] [PMID: 29391790]
[http://dx.doi.org/10.1016/j.nano.2018.04.011] [PMID: 29680672]
[http://dx.doi.org/10.1208/s12249-017-0830-1] [PMID: 28681330]
[http://dx.doi.org/10.1101/314161]
[http://dx.doi.org/10.3121/cmr.4.3.218] [PMID: 16988102]
[PMID: 28255378]
[PMID: 26839517]
[http://dx.doi.org/10.4161/onci.24523] [PMID: 23762812]
[http://dx.doi.org/10.1006/jmbi.1997.1281] [PMID: 9368648]
[http://dx.doi.org/10.1006/bbrc.2001.4327] [PMID: 11178986]
(b) Bagalkot, V.; Farokhzad, O.C.; Langer, R.; Jon, S. An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform. Angew. Chem. Int. Ed. Engl., 2006, 45(48), 8149-8152.
[http://dx.doi.org/10.1002/anie.200602251] [PMID: 17099918]
[http://dx.doi.org/10.7150/thno.10202] [PMID: 25553096]
[http://dx.doi.org/10.1039/C5AN01824B] [PMID: 26864075]
[http://dx.doi.org/10.1016/j.nano.2017.04.002] [PMID: 28414074]
[http://dx.doi.org/10.1158/1535-7163.MCT-06-0172] [PMID: 17172400]
[http://dx.doi.org/10.1016/j.molonc.2015.03.012] [PMID: 25911416]
[http://dx.doi.org/10.1161/CIRCRESAHA.114.305951] [PMID: 26195220]
(b) Berg, K.; Lange, T.; Mittelberger, F.; Schumacher, U.; Hahn, U. Selection and Characterization of an α6β4 Integrin blocking DNA Aptamer. Mol. Ther. Nucleic Acids, 2016, 5.
[http://dx.doi.org/10.1038/mtna.2016.10]
[http://dx.doi.org/10.1158/0008-5472.CAN-04-2550] [PMID: 15520166]
[http://dx.doi.org/10.1073/pnas.0809154105]
[http://dx.doi.org/10.3322/CA.2007.0010] [PMID: 18287387]
[http://dx.doi.org/10.1158/0008-5472.CAN-05-4583] [PMID: 16778167]
[http://dx.doi.org/10.1016/j.bios.2015.07.064] [PMID: 26257183]
[http://dx.doi.org/10.1002/elps.200900141] [PMID: 19722212]
[http://dx.doi.org/10.3762/bjoc.14.80] [PMID: 29765474]
[PMID: 23016584]
[http://dx.doi.org/10.1038/srep32062] [PMID: 27576789]
[http://dx.doi.org/10.3762/bjnano.5.107] [PMID: 25161829]
[http://dx.doi.org/10.1002/jin2.33]
[http://dx.doi.org/10.1021/mp200007b] [PMID: 21510670]
[http://dx.doi.org/10.1016/j.biomaterials.2016.05.015] [PMID: 27209258]
b) Yu, D-G.; Zheng, X-L.; Yang, Y.; Li, X-Y.; Williams, G.R.; Zhao, M. Immediate release of helicid from nanoparticles produced by modified coaxial electrospraying. Appl. Surf. Sci., 2019, 473, 148-155.
[http://dx.doi.org/10.1016/j.apsusc.2018.12.147]
[http://dx.doi.org/dx.doi.10.3390/nano9040532] [PMID: 30987129]